In recent years it has become clear that genetics plays a key role in the development of Parkinson’s. By understanding genetic pathways, the hope is that a novel drug to prevent or slow down Parkinson’s development can be produced.
One of the most common genes implicated in Parkinson’s disease is glucocerebrosidase (GBA). About 10% of UK Parkinson’s patients carry a mutation in this gene. In this 25-minute video “From genes to therapy” , Dr. Stephen Mullin described how this gene causes Parkinson’s disease, and outlined some exciting recent advances in drug development.
Dr. Mullin holds a clinical lectureship in Neurology at The Faculty of Medicine and Dentistry at Plymouth University.